[表皮生长因子受体突变可切除非小细胞肺癌患者围手术期靶向治疗的进展与讨论]。

Q4 Medicine

中国肺癌杂志 Pub Date : 2024-05-20 DOI:10.3779/j.issn.1009-3419.2024.106.11

Peng Song, Yong Cui

{"title":"[表皮生长因子受体突变可切除非小细胞肺癌患者围手术期靶向治疗的进展与讨论]。","authors":"Peng Song, Yong Cui","doi":"10.3779/j.issn.1009-3419.2024.106.11","DOIUrl":null,"url":null,"abstract":"Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches.\u2029.","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 5","pages":"383-390"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11183319/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Progress and Discussion of Perioperative Targeted Therapy in Patients \\u2029with EGFR-mutated Resectable Non-small Cell Lung Cancer].\",\"authors\":\"Peng Song, Yong Cui\",\"doi\":\"10.3779/j.issn.1009-3419.2024.106.11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches.\\u2029.\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"27 5\",\"pages\":\"383-390\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11183319/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2024.106.11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.106.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

肺癌仍然是全球癌症死亡的首要原因。非小细胞肺癌（NSCLC）是肺癌的主要病理类型，约占 80%。大约 30% 的非小细胞肺癌患者在确诊时处于可切除的早期和中期。最近，表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的可切除NSCLC的辅助靶向治疗中取得了重大突破，并被指南推荐用于临床。在这篇综述中，我们总结了EGFR突变可切除NSCLC围手术期辅助靶向治疗的临床研究进展，并讨论了临床研究中的关键问题。.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Progress and Discussion of Perioperative Targeted Therapy in Patients  with EGFR-mutated Resectable Non-small Cell Lung Cancer].

Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches. .

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

5131

审稿时长

14 weeks

期刊介绍： Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.